Investment objective & strategy
As of Dec. 29, 2025 · prospectusObjective. The Health & Biotechnology Portfolio seeks long-term capital growth.
Strategy. The Portfolio will normally invest at least 80% of its total assets in equity securities of U.S. and foreign healthcare companies and biotechnology companies, regardless of their stock market value (or market capitalization). Equity securities include common stocks, preferred stocks, securities convertible into common stocks and warrants. The Adviser utilizes a top-down investment approach focused on long-term economic trends. The Adviser begins with the overall outlook for the economy, then seeks to identify specific industries with attractive characteristics and long-term growth potential. Ultimately, the Adviser seeks to identify high-quality companies within the selected industries and to acquire them at attractive prices. The Advisers stock selection process is based on an analysis of individual companies fundamental values, such as earnings growth … The Portfolio will normally invest at least 80% of its total assets in equity securities of U.S. and foreign healthcare companies and biotechnology companies, regardless of their stock market value (or market capitalization). Equity securities include common stocks, preferred stocks, securities convertible into common stocks and warrants. The Adviser utilizes a top-down investment approach focused on long-term economic trends. The Adviser begins with the overall outlook for the economy, then seeks to identify specific industries with attractive characteristics and long-term growth potential. Ultimately, the Adviser seeks to identify high-quality companies within the selected industries and to acquire them at attractive prices. The Advisers stock selection process is based on an analysis of individual companies fundamental values, such as earnings growth potential and the quality of corporate management. Companies described as Health Care Equipment and Supplies, Health Care Provider Services, Pharmaceutical or Biotechnology Companies under the North American Industry Classification System are considered healthcare or biotechnology companies for purposes of investment by the Portfolio. These companies are principally engaged in: the design, manufacture or sale of products or services used for or in connection with health, medical, or personal care such as medical, dental and optical supplies or equipment; research and development of pharmaceutical products and services; the operation of healthcare facilities such as hospitals, clinical test laboratories and convalescent and mental healthcare facilities; and the design, manufacture, or sale of healthcare-related products and services, research, development, manufacture or distribution of products and services relating to human health care, pharmaceuticals, agricultural and veterinary applications and the environment; and manufacturing and/or distributing biotechnological and biomedical products, devices or instruments or provide materials, products or services to the foregoing companies. Factors considered include growth potential, earnings, valuation, competitive advantages and management. When market or financial conditions warrant, the Portfolio may also make temporary investments in investment grade debt securities. Such investment strategies could result in the Portfolio not achieving its investment objective.
Top holdings
As of Feb. 28, 2026 · N-PORT| Security | Ticker | Value | % of fund |
|---|---|---|---|
| CARDINAL HEALTH INC | — | $786.03K | 6.77% |
| MCKESSON CORP | — | $682.27K | 5.88% |
| AMGEN INC | — | $680.06K | 5.86% |
| CENCORA INC | — | $626.31K | 5.40% |
| JAZZ PHARMACEUTI | — | $615.85K | 5.31% |
| UNITED THERAPEUTICS CORP DEL | — | $584.52K | 5.04% |
| Novartis AG | — | $529.47K | 4.56% |
| REGENERON PHARMACEUTICALS INC | — | $523.72K | 4.51% |
| GILEAD SCIENCES INC | — | $456.98K | 3.94% |
| JOHNSON&JOHNSON | — | $452.14K | 3.90% |
Portfolio moves
Nov 30, 2025 → Feb 28, 2026How many positions this fund opened, exited, grew, trimmed, or left unchanged between its two most recent N-PORT snapshots — net changes between point-in-time reports, not a trade log.
Similar funds
Funds whose portfolios most overlap this one, by weight| Fund | Overlap | Net exp. |
|---|---|---|
| LIVE OAK HEALTH SCIENCES FUND · LOGSX | 83% | 1.04% |
| DWS Health and Wellness Fund · SUHAX, SUHCX, SCHLX, SUHIX | 38% | 1.03% |
| PROFUND VP HEALTH CARE | 37% | 1.68% |
Advisers
| Firm | Role |
|---|---|
| Saratoga Capital Management, LLC | Adviser |
| Oak Associates, Ltd. | Sub-adviser |
Footnotes
- Expense ratio as of December 29, 2025, from the fund's prospectus.
- Net assets and holdings count as of February 28, 2026, from the fund's N-PORT filing.
- Total return for calendar year 2025, before tax and after fund expenses. Computed by compounding the twelve monthly total returns the fund reported in its SEC N-PORT filings for 2025 (the latest prospectus does not yet chart this year).
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.